RTFCCR-MRA Team Science Awards on Improving the Early Detection, Diagnosis, and Risk of Melanoma Stratification Grant
Funding Amount
Up to US $900,000
Deadline
Deadline not published
Grant Type
Foundation
Overview
The RTFCCR-MRA Team Science Awards aim to enhance early detection and diagnosis of melanoma through patient-engaged clinical validation studies or pilot trials. These awards prioritize innovative methods with supporting preliminary data, fostering collaboration between researchers and patient partners in the research process. By addressing significant unmet needs in melanoma care, this funding opportunity invites diverse research groups to develop effective detection and risk stratification strategies for melanoma, ultimately improving patient outcomes.
RTFCCR-MRA Team Science Awards on Melanoma Early Detection, Diagnosis, and Risk Stratification
The MRA and RTFCCR will jointly support a Team Science Award for clinical validation studies or pilot (phase I) clinical trials aimed at improving melanoma early detection, diagnosis, and risk stratification. Patient involvement must be actively demonstrated throughout the full life cycle of the work, including planning and dissemination.
It encompasses the active and collaborative interaction between patient partners and researchers across all stages of the research process from conception to results distribution, where research decision making is supported by patient partners’ contributions, recognizing their specific experiences, values, and expertise.
These awards will support innovative approaches with preliminary data, where funding is required to advance the validation of tests, technologies, or devices. We welcome applications from all research groups with a track record in melanoma. Grant applicants should actively involve patient partners in the protocol design.
Purpose:
RTFCCR and MRA have identified early detection and accurate diagnosis of melanoma and the identification of high-risk patients whose primary tumors are most likely to progress as significant areas of unmet need. The purpose of this call for proposals is to solicit high quality research proposals focused on improving the early detection, diagnosis, and risk stratification of melanoma.
What Melanoma Research Alliance Foundation actually gave
Source: IRS Form 990, 2024
- Grants in 2024
- 29
- Total given
- $11.92M
- Median grant
- $255K
- Range
- $12K–$1.16M
- By dollars: New York 26%, California 22%, Massachusetts 19%. Top recipient cities: Boston, MA; Philadelphia, PA; New York, NY.
- 0% of grants with a stated purpose were for general or operating support.
- 55% of recipients were new grantees, not repeat recipients.
Example grants
Columbia University Irving Medical Center · New York, NY
1 team science award, 1 young investigator award
$1.16M
Memorial Sloan Kettering Cancer Center (MSK) · New York, NY
2 pilot award, 1 team science award
$1.09M
Massachusetts General Hospital (Mass General) · Boston, MA
1 next steps: advancing drug discovery to identify new therapies award, 1 team science…
$1.02M
The Regents of the University of California San Francisco · San Francisco, CA
1 team science award, 1 pilot award
$1M
Dana-Farber Cancer Institute · Boston, MA
1 team science award, 1 next steps: melanoma biomarker development award
$975K
Focus Areas & Funding Uses
Fields of Work
- Science research
- Cancer
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
Melanoma Research Alliance: Special Opportunity Team Science Awards Grant
Melanoma Research Alliance Foundation
Amount
Up to US $900,000
Deadline
Deadline not published
MRA Dermatology Career Development Award
Melanoma Research Alliance Foundation
Amount
Varies
Deadline
Deadline not published
Special Opportunity Team Science Academic-Industry Partnership Award Grant
Melanoma Research Alliance Foundation
Amount
Up to US $900,000
Deadline
Deadline not published
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
National Institutes of Health
Amount
Up to $499,999
Deadline
January 7, 2027
Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
October 8, 2027
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Up to $350,000
Deadline
November 6, 2026
Ready to apply for RTFCCR-MRA Team Science Awards on Improving the Early Detection, Diagnosis, and Risk of Melanoma Stratification Grant?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found RTFCCR-MRA Team Science Awards on Improving the Early Detection, Diagnosis, and Risk of Melanoma Stratification Grant. Now let's win it.